Coronavirus: we may have recall vaccinations for years

Immunologist Alberto Mantovani compares the coronavirus vaccination with the influenza one

0
261
Coronavirus

Italian immunologist Aberto Mantovani told La Repubblica people may expect to have recall vaccination for coronavirus and its variants for years. So, he said, we have to produce a large number of vaccines in order to guarantee the population all the necessary doses. “Italy once had a great tradition; it exported more vaccines than those which imported. I believe the valorization of our capability to innovate and fabricate within this sector is strategic. We must regain that great tradition and come back to produce to have vaccines for the variants”.

Coronavirus: may the population have recall vaccinations for years?

The population may have to make recall vaccinations for years in order to tackle Covid-19 and its variants. These are the words of Italian immunologist Alberto Mantovani, who explained his hypothesis concerning the future of the health sector in Italy, as well as worldwide. The immunologist argued we need to come back to produce a large number of vaccines in order to guarantee the necessary doses to everyone. “Italy once had a great tradition; it exported more vaccines than those which imported. I believe the valorization of our capability to innovate and fabricate within this sector is strategic. We must regain that great tradition and come back to produce to have vaccines for the variants”, Mantovani told La Repubblica.

Replying to a question concerning the vaccination campaign among elders, the immunologist responded: “I absolutely agree. It is not highlighted enough that by vaccinating elders we put in safety both them and ourselves. With wide coverings of frail people, we free intensive cares and places where to care cancer and cardiovascular problems”.

Mantovani’s opinions regarding AstraZeneca

As regards the side effects of AstraZeneca, instead: “The United Kingdom inoculated 20 million people and registered 79 thrombosis cases. We are talking about one case every 250 thousand, a low risk. Several weeks ago, a scientific work estimated that 8% and 11% of Covid patients may have to struggle against venous thromboembolism. This data leads up to 20-25% among those who are in intensive care.  All higher risks than rare cases related to the vaccine”. Eventually talking about the vaccination campaign worldwide, Mantovani explained by the end of the year between 8 and 11 billion doses will be produced. In this way, issues may be almost totally sorted out.


You can also read: NASA announces new blog about Ingenuity

LEAVE A REPLY

Please enter your comment!
Please enter your name here